ELVN

Enliven Therapeutics (ELVN)

About Enliven Therapeutics (ELVN)

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Details

Daily high

$42.90

Daily low

$40.02

Price at open

$41.56

52 Week High

$48.53

52 Week Low

$14.78

Market cap

2.5B

Dividend yield

0.00%

Volume

9,289

Avg. volume

716,677

P/E ratio

-24.49

Enliven Therapeutics News